JSKN003 vs. doctor's choice for HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer has returned or spread and cannot be removed with surgery.
- Your tumor is HER2-low (IHC 1+ or 2+ with negative ISH test).
- You have already received 1 to 2 types of chemotherapy for advanced breast cancer.
- Your cancer has gotten worse during or after your most recent treatment.
- You have at least one tumor that can be measured with a scan (outside the brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (KJ015) for people with solid tumors that have a protein called HER2. It’s for patients whose cancer has continued to grow despite previous treatments, and who are relatively well overall.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug combination (JSKN003) for people with HER2-positive gastric cancer. It is for patients who have not yet received treatment, either for advanced disease or before surgery to remove the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.